“With a late December PDUFA date and factoring in the time needed for site activation, we expect revenue from anitocel to begin in early 2027.”

In context

“ccess and global reach of our cell therapies. For example, in April, Tecartus received full FDA approval in adult relapsed or refractory mantle cell lymphoma, adding data on patients who are BTK inhibitor–naive. This important work of increasing awareness and physician comfort with CAR T helps set the stage for the potential launch of our next-generation products. Turning to anitocel, and with the close of the Arcellx acquisition last week, we are ramping up our detailed launch preparations for what we believe could be a best-in-disease multiple myeloma therapy. Adding Kite's end-to-end expertise in cell therapy to anitocel’s demonstrated deep, durable efficacy and differentiated safety profile positions anitocel to maximize its potential in the $3.5 billion fourth-line-plus CAR T market. With a late December PDUFA date and factoring in the time needed for site activation, we expect revenue from anitocel to begin in early 2027. As we wrap up the first quarter and look forward to up to four additional launches this year, shown on slide 14, I want to recognize our commercialization teams for their exceptional execution in driving another strong quarter in Q1, and thank them for their commitment to growing patient impact in the second quarter and beyond. And with that, I will hand the call over to Dietmar. Dietmar Berger: Thank you, Joanna, and good afternoon, everyone. I am pleased to share that the strong momentum across our research and clinical programs has accelerated since our full-year earnings in February. This is supported by disciplined portfolio prioritization and strong execution. With the close of the Arcellx acquisition, our pipeline now consists of 47 clinical programs spanning our portfolio of first”